SMN1 and proximal spinal muscular atrophy: Onasemnogene abeparvovec-xioi (Zolgensma®) is a novel gene therapy for pediatric patients under 2 years of age with SMA with bi-allelic mutations in SMN1 and has an expected unit price of US$2.15 million [30].